Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.390,04+0,87 %

Gold2.655,89+0,99 %

Öl (Brent)79,04-0,57 %

Dow Jones42.865,63+0,97 %

US Tech 10020.269,38+0,14 %

EUR/USD1,09380+0,02 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

60 Degrees Pharmaceuticals Aktie

Aktie

ISIN: US83006G2030 SYM: SXTP Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

1,0500

USD

-1,42 %

-0,0151 USD

Letzter Kurs 02:00:00 NYSE

Geldkurs

22:02:00

1,0200

USD

900 STK

Briefkurs

22:02:00

1,0800

USD

100 STK

60 Degrees Pharmaceuticals Aktie kaufen

Neueste Nachrichten

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA NDA in Support of SJ733 Phase IIb Study 12.08.24 · globenewswire · 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc. Announces 1: 12 Reverse Stock Split 06.08.24 · globenewswire · 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade Support 25.07.24 · globenewswire · 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study 19.07.24 · globenewswire · 60 Degrees Pharmaceuticals
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment 09.07.24 · globenewswire · 60 Degrees Pharmaceuticals
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind 27.06.24 · globenewswire · 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis 11.06.24 · globenewswire · 60 Degrees Pharmaceuticals
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind 30.05.24 · globenewswire · 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study 20.05.24 · globenewswire · 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results 15.05.24 · globenewswire · 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases 08.05.24 · globenewswire · 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required 02.05.24 · globenewswire · 60 Degrees Pharmaceuticals

1
2

Meistgelesen

12 Monate

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA NDA in Support ... 276 Leser
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements 264 Leser
60 Degrees Pharmaceuticals, Inc. Announces 1: 12 Reverse Stock Split 204 Leser
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results 188 Leser
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, ... 184 Leser
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting 172 Leser
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter ... 156 Leser
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine ... 156 Leser
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus ... 148 Leser
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and ... 140 Leser